Detalles de la búsqueda
1.
Retrospective Data Analysis of Patients With Metastatic Lung Adenocarcinoma With or Without KRAS-Mutation or TTF1-Expression.
Cancer Control
; 29: 10732748221126949, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36355617
2.
[30- and 90-day Lethality in Patients with Stage IV Lung Cancer Depending on the Primary Therapy]. / 30- und 90-Tage-Letalität bei Patienten mit Lungenkarzinom im Stadium IV in Abhängigkeit der Primärtherapie.
Pneumologie
; 75(12): 950-959, 2021 Dec.
Artículo
en Alemán
| MEDLINE | ID: mdl-34298565
3.
Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
BMC Cancer
; 18(1): 333, 2018 03 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29587656
4.
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
BMC Cancer
; 18(1): 135, 2018 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29402243
5.
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
Invest New Drugs
; 31(1): 175-82, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22752690
6.
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
PLoS One
; 18(10): e0292307, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37847688
7.
Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life.
BMC Cancer
; 12: 14, 2012 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-22244076
8.
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.
Transl Lung Cancer Res
; 11(10): 2010-2021, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36386456
9.
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
J Thorac Oncol
; 16(9): 1547-1558, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33607312
10.
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.
Curr Med Res Opin
; 33(5): 937-941, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28277871
11.
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.
Lung Cancer (Auckl)
; 8: 217-229, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158696
12.
Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
J Clin Oncol
; 23(33): 8389-95, 2005 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16293869
13.
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer.
Clin Lung Cancer
; 8(2): 135-9, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17026815
14.
Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.
Clin Lung Cancer
; 7(5): 338-43, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16640806
15.
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Clin Lung Cancer
; 7(2): 133-7, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16179101
16.
CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
Clin Lung Cancer
; 16(6): 447-56, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26094080
17.
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
Lung Cancer
; 90(3): 397-404, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26791798
18.
EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study.
Cancer Epidemiol Biomarkers Prev
; 24(8): 1254-61, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26070531
19.
Treatment of brain metastases from lung cancer: chemotherapy.
Lung Cancer
; 45 Suppl 2: S253-7, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15552807
20.
A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer.
Case Rep Oncol
; 7(2): 435-43, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25126073